Aug 17, 2023 / 02:00PM GMT
Arthur He - H.C. Wainwright & Co., LLC - Analyst
Greetings, everyone. My name is Arthur He, a senior biotech analyst at H.C. Wainwright. Thanks for joining us to have a conversation with the management of LAVA Therapeutics: Mr. Steve Hurly, their CEO; and Mr. Fred Powell, the Chief Financial Officer; and Dr. Charles Morris, the Chief Medical Officer.
LAVA Therapeutics is a clinical-stage biotechnology company focused on developing gamma bodies to harness Gammabody to harness gamma-delta T cells for cancer treatment. The company currently has one drug in clinical development and several preclinical candidates.
To discuss the company's development strategy in 2023 and beyond, I welcome Steve, Fred, and Charlie to this fireside chat. Good morning, Steve, Fred, and Charlie.
Steve Hurly - LAVA Therapeutics, N.V. - CEO & Board Director
Good morning, Arthur. Thanks for having us.
Fred Powell - LAVA Therapeutics, N.V. - CFO
Good morning.
Charles Morris - LAVA
LAVA Therapeutics NV at HC Wainwright Immune Cell Engager Virtual Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
